- Molecular NameEthotoin
- SynonymEthotoine [INN-French]; Ethotoinum [INN-Latin]; Etotoina [INN-Spanish]
- Weight204.229
- Drugbank_IDDB00754
- ACS_NO86-35-1
- Show 3D model
- LogP (experiment)1.083
- LogP (predicted, AB/LogP v2.0)1.47
- pka8.5
- LogD (pH=7, predicted)1.45
- Solubility (experiment)Soluble
- LogS (predicted, ACD/Labs)(ph=7)-1.73
- LogSw (predicted, AB/LogsW2.0)1.6
- Sw (mg/ml) (predicted, ACD/Labs)3.45
- No.of HBond Donors1
- No.of HBond Acceptors4
- No.of Rotatable Bonds2
- TPSA49.41
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn anticonvulsant drug used in the treatment of epilepsy. It is a hydantoin, similar to phenytoin. Ethotoin lacks phenytoin's side effects of gingival hyperplasia and hirsutism, however it is less effective. This, combined with the need for frequent dosing has limited its usefulness. Ethotoin is no longer widely used.
- Absorption_valueN/A
- Absorption (description)Readily absorbed after oral administration.
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmExtensively metabolised by N-desethylation and ring cleavage, 5-hydroxylation and p-hydroxylation of the phenyl ring.
- Half life3~9 h
- ExcretionDuring chronic therapy, less than 5% of the dose is excreted in the urine in 24 h as unchanged drug, together with 5 to 14% of the dose as desethylethotoin, 17 to 35% as 5-hydroxyethotoin, 14 to 32% as conjugated p-hydroxyethotoin and small amounts of other phenyl-substituted oxidation products. 2-Phenylhydantoic acid may account for about 10% of the dose.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityThe estimated minimum lethal dose is 5 g.
- LD50 (rat)N/A
- LD50 (mouse)N/A